Ipsen: agreement for acquisition of Clementia

(CercleFinance.com) - Ipsen has announced obtaining an agreement to acquire Clementia Pharmaceuticals, whose advanced phase palovarotene molecule has achieved pediatric disease status and major therapeutic progress for an ultra-rare bone disease, with approval set to be received in 2020.


The group has committed itself to acquiring Clementia shares for 25 dollars each at the closing of the deal, to which are added certificates of guaranteed value amounting to six dollars, which are related to the indication in multiple osteochondromas, for a total of up to 1.31 billion dollars.

The transaction will lead to a significant increase in the group's net debt and is leading it to now target an operating margin of around 30% in 2019 (instead of 31%), excluding any additional growth investments in the R&D portfolio.


Copyright (c) 2019 CercleFinance.com. All rights reserved.